Tvardi Therapeutics Announces Presentation of REVERT LIVER CANCER Phase 2 Clinical Trial Using TTI-101, A Novel STAT3 Inhibitor, at 2024 ASCO Gastrointestinal Cancers Symposium streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Peel Therapeutics to Present Data on its TOP1 Inhibitor PEEL-224 at the Connective Tissue Oncology Society Annual Meeting and Society for Immunotherapy of Cancer Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Imugene Ltd HER-Vaxx and CF33 platforms feature at ASCO Gastrointestinal Cancers Symposium proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in.
/PRNewswire/ Eisai announced today the presentation of six abstracts across various gastrointestinal cancers during the 2022 American Society of Clinical.